Basket | Login | Register


Anavex Life Sciences receives approval to start Phase II/III trial for AD drug ANAVEX2-73

Monday 09 July 2018

On 9 July, Anavex Life Sciences Corp, a biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD), announced that is has received approval by the Australian Human Research Ethics Committee to initiate its 48-week double-blind, randomised and placebo-controlled Phase II/III study investigating the safety and efficacy of ANAVEX2-73 for the treatment of early AD. This clinical trial is expected to recruit approximately 450 participants in Australia and North US. Primary and secondary endpoints will evaluate safety and both cognitive and functional efficacy. Results from the Phase IIa study showed improvement in exploratory endpoints of both cognition and function. The company also announced that it has received approval to initiate Phase II clinical trial of ANAVEX2-73 for the treatment of Parkinson’s disease dementia in Europe.